Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aileron Announces Positive Data for LTI-03 in Idiopathic Pulmonary Fibrosis
Details : LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Inapplicable
November 13, 2024
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulanemadlin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Advancium Health
Deal Size : Undisclosed
Deal Type : Acquisition
Aileron And Advancium Sign Deal for ALRN-6924 Retinoblastoma Therapy
Details : Through the acquisition, Advancium will expand its oncology portfolio by acquiring ALRN-6924 (sulanemadlin), which is being evaluated for the treatment of retinoblastoma.
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Undisclosed
October 31, 2024
Lead Product(s) : Sulanemadlin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Advancium Health
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aileron Completes Enrollment in Phase 1b Trial of LTI-03 in Pulmonary Fibrosis
Details : LTI-03 is a novel, Caveolin-1-related peptide that addresses both inhibition of pro-fibrotic signaling & survival of critical epithelial cells. It is being developed for idiopathic pulmonary fibrosis.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Titan Partners Group LLC
Deal Size : $40.0 million
Deal Type : Public Offering
Aileron Completes $40 Million Underwritten Registered Direct Offering
Details : The proceeds will advance the clinical development of Aileron’s lead candidate, LTI-03, currently in early-stage trials for idiopathic pulmonary fibrosis.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Undisclosed
March 05, 2024
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Titan Partners Group LLC
Deal Size : $40.0 million
Deal Type : Public Offering
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aileron Therapeutics Reports Positive Data from Phase 1b Trial Of LTI-03 in IPF
Details : LTI-03 is a novel, Caveolin-1-related peptide that addresses both inhibition of pro-fibrotic signaling and survival of critical epithelial cells. Being developed for idiopathic pulmonary fibrosis.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Inapplicable
January 05, 2024
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Titan Partners Group LLC
Deal Size : $4.6 million
Deal Type : Public Offering
Positive Initial Data Reported from Immutep's Efti Combined with Radiotherapy in Phase II
Details : The net proceeds will be used to advance the development of LTI-03, a peptide representing an important region of the Caveolin 1 (Cav1) protein, for the treatment of idiopathic pulmonary fibrosis.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Undisclosed
January 05, 2024
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Titan Partners Group LLC
Deal Size : $4.6 million
Deal Type : Public Offering
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Clear Street LLC
Deal Size : $18.0 million
Deal Type : Private Placement
Aileron Therapeutics Announces Acquisition of Lung Therapeutics
Details : Aileron intends to use the proceeds primarily to complete the ongoing Phase 1b clinical study of LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis.
Product Name : LTI-03
Product Type : Peptide
Upfront Cash : Undisclosed
October 31, 2023
Lead Product(s) : LTI-03
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Clear Street LLC
Deal Size : $18.0 million
Deal Type : Private Placement
Lead Product(s) : Sulanemadlin
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALRN-6924 is an MDM2/MDMX inhibitor that leverages Aileron’s proprietary peptide drug technology. The primary endpoint of the Phase 1b open-label trial was duration and incidence of severe neutropenia in cycle 1.
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
February 21, 2023
Lead Product(s) : Sulanemadlin
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulanemadlin,Paclitaxel
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Non-clinical data demonstrated principle that ALRN-6924 can temporarily arrest cell cycle in human scalp hair follicles and their stem cells also ALRN-6924-induced cell cycle arrest protected hair follicles from paclitaxel-induced toxicity and irreversib...
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
October 05, 2022
Lead Product(s) : Sulanemadlin,Paclitaxel
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulanemadlin
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary endpoints are duration and incidence of severe neutropenia (Grade 4) in cycle 1. Secondary endpoints include the chemoprotective effect of ALRN-6924 on chemotherapy-induced alopecia, as well as other hematologic and non-hematologic toxicities...
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
September 30, 2022
Lead Product(s) : Sulanemadlin
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable